Antibodies that specifically bind peptides associated with the primary immunodeficiencies: Wiskott-Aldrich syndrome and x-linked agammaglobulinemia
AssigneeSeattle Children's Hospital
InventorsSihoun Hahn, Christopher Collins, Fan Yi, Remwilyn Dayuha
Life of this patent
Estimating the term…
Abstract
The current disclosure provides antibodies that bind to peptides associated with the primary immunodeficiency disorders (PIDD) Wiskott-Aldrich Syndrome (WAS) and X-linked agammaglobulinemia (XLA). The antibodies can be used in peptide immunoaffinity enrichment coupled to selected reaction monitoring mass spectrometry (immuno-SRM) assays for clinical diagnosis and newborn screening of WAS and XLA, among other uses.
Claims20
An antibody or antigen binding fragment thereof that binds to Wiskott-Aldrich Syndrome protein (WASp) 289 signature peptide for Wiskott-Aldrich Syndrome (WAS) of SEQ ID NO:
- 1 or Bruton's Tyrosine Kinase (BTK) 545 signature peptide for X-linked agammaglobulinemia (XLA) of SEQ ID NO:
- 2, the antibody or antigen binding fragment comprising:
- (A) a heavy chain variable (VH) domain comprising a CDRH1 having the sequence of SEQ ID NO:
- 3, a CDRH2 having the sequence of SEQ ID NO:
- 4, and a CDRH3 having the sequence of SEQ ID NO:
- 5, and a light chain variable (VL) domain comprising:
- a CDRL1 having the sequence of SEQ ID NO:
- 6, a CDRL2 having the sequence of SEQ ID NO:
- 7, and a CDRL3 having the sequence of SEQ ID NO:
- 8 or
- (B) a VH domain comprising a CDRH1 having the sequence SEQ ID NO:
- 9, a CDRH2 having the sequence of SEQ ID NO:
- 10, and a CDRH3 having the sequence of SEQ ID NO:
- 11, and a VL domain comprising:
- a CDRL1 having the sequence of SEQ ID NO:
- 12, a CDRL2 having the sequence of SEQ ID NO:
- 13, and a CDRL3 having the sequence of SEQ ID NO:
- 14.
Dependencies are inferred from the claim text.